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Abstract
Background: Preeclampsia is a common and heterogeneous vascular syndrome of pregnancy. Its genetic risk
profile is yet unknown and may vary between individuals and populations. The rs4606 3′ UTR polymorphism of the
Regulator of G-protein signaling 2 gene (RGS2) in the mother has been implicated in preeclampsia as well as in the
development of chronic hypertension after preeclampsia. The RGS2 protein acts as an inhibitor of physiological
vasoconstrictive pathways, and a low RGS2 level is associated with hypertension and obesity, two conditions that
predispose to preeclampsia. We genotyped the rs4606 polymorphism in 1339 preeclamptic patients and in 697
controls from the Finnish Genetics of Preeclampsia Consortium (FINNPEC) cohort to study the association of the
variant with preeclampsia.
Results: No association between rs4606 and preeclampsia was detected in the analysis including all women.
However, the polymorphism was associated with preeclampsia in a subgroup of overweight women (body mass
index ≥ 25 kg/m2, and < 30 kg/m2) (dominant model; odds ratio, 1.64; 95 % confidence interval, 1.10–2.42).
Conclusions: Our results suggest that RGS2 might be involved in the pathogenesis of preeclampsia particularly
in overweight women and contribute to their increased risk for hypertension and other types of cardiovascular
disease later in life.
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coupled receptor; NE, norepinephrine; RAS, renin-angiotensin system; RGS, regulator of G-protein signaling;
RGS2, regulator of protein signaling 2 gene; α1, α1-adrenergic receptor
Background
Preeclampsia is a complex syndrome of pregnancy
characterized by hypertension, proteinuria and various
metabolic disturbances resembling those seen in the
metabolic syndrome [1]. It affects 2–8 % of pregnancies,
and is one of the leading causes of maternal and peri-
natal mortality worldwide [2]. Insufficient placental per-
fusion is currently considered a central phenomenon in
the development of preeclampsia [3]. However, multiple
genetic [4, 5] and metabolic risk factors are likely impli-
cated in the maternal response, which includes the
development of systemic inflammation, endothelial
dysfunction and an imbalance of angiogenic and anti-
angiogenic factors [3, 6–8]. The spectrum of preeclamp-
sia symptoms and disease severity is wide and several
pathogenic pathways are likely to contribute to different
subtypes of the disease [9, 10]. Preeclampsia is associ-
ated with an increased risk of cardio- and cerebrovascu-
lar diseases [11]. Furthermore, being overweight
predisposes to both cardiovascular diseases and pre-
eclampsia [12], suggesting that these conditions may
share genetic and other risk factors. Whether the genetic
risk profile of women with preeclampsia differs accord-
ing to the clinical heterogeneity of the syndrome
remains undetermined.
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One of the genes implicated in blood pressure regula-
tion, the regulator of G-protein signaling 2 gene (RGS2),
has recently been suggested to be associated with pre-
eclampsia and with the development of chronic hyper-
tension after pregnancy [13, 14]. Regulator of G-protein
signaling (RGS) proteins control the activity of the Gα
subunit located in the intracellular side of G protein-
coupled receptors (GPCR). They enhance GTP hydroly-
sis in the Gα subunit and thereby inhibit the receptor
(Fig. 1). RGS2 belongs to a group of RGS proteins that
are involved in the regulation of blood pressure, and acts
as an inhibitor of the GPCR-mediated vasoconstrictor
signaling pathways [15] activated by vasoconstrictive li-
gands, such as angiotensin II, vasopressin and norepin-
ephrine [16–18]. It is well known that there is increased
sensitivity to angiotensin II in preeclampsia compared to
normal pregnancy [19]. Also elevated levels of vasopres-
sin and norepinephrine have been linked to preeclamp-
sia [20–22]. The 3′ UTR C1114G polymorphism of
RGS2 (rs4606) is associated with low RGS2 levels [23]
and has been connected to hypertension [23] and obesity
[24]. In addition, rs4606 has been linked to anxiety
disorders [25] and to posttraumatic stress disorder [26].
The aim of this study was to investigate whether
rs4606 in RGS2 is associated with preeclampsia in a
Finnish case-control cohort, with specific focus on the




We studied 1339 preeclamptic women and 697 women
without preeclampsia from the Finnish Genetics of
Preeclampsia Consortium (FINNPEC) cohort. The sam-
ples and data were collected during 2008–2011 at the
five Finnish university hospitals. The inclusion criteria of
the FINNPEC cohort were age above 18 years, a single-
ton pregnancy and sufficient language skills for under-
standing the research information and consent forms. In
our study we excluded the women with a previous
preeclamptic pregnancy or chronic or gestational
hypertension, the pregnancies with small for gesta-
tional age infant and/or, placental insufficiency from
the control group.
Obstetric and perinatal data
The clinical data including information on preeclampsia
in previous pregnancies, prepregnancy weight and
height, smoking before and during pregnancy, blood
pressure and proteinuria during pregnancy and perinatal
outcomes were collected from the patient records. Pre-
pregnancy weight was self-reported at the first antenatal
visit, which usually takes place around 10th week of ges-
tation and includes a measurement of current weight.
Preeclampsia was defined as systolic blood pressure ≥
140 mmHg or diastolic blood pressure ≥90 mmHg
measured at least twice after 20 weeks of gestation and
proteinuria ≥0.3 g/24 h, or ≥1+ reading on dipstick in a
random urine sample at least twice with no evidence of
a urinary tract infection. Preeclampsia was defined
superimposed if elevated blood pressure predated mid-
pregnancy, including both women with chronic hyper-
tension and de novo hypertension before midpregnancy.
Preeclampsia was categorized severe in the presence of
systolic blood pressure ≥160 mmHg, diastolic blood
pressure ≥110 mmHg, proteinuria ≥5 g/24 h or clinically
severe symptoms of preeclampsia, including clonus or
respiratory distress. Each diagnosis was confirmed inde-
pendently from medical records by a research nurse and
a research physician. The study participants were catego-
rized according to their prepregnancy BMI to normal
weight (BMI <25 kg/m2), overweight (BMI ≥25 kg/m2
and <30 kg/m2) and obese (BMI ≥30 kg/m2). Placental
insufficiency was defined as relative umbilical artery
resistance index ≥ +2 SD or relative umbilical artery
pulsatility index ≥ +2 SD for gestational age [27]. Relative
birth weight (SD, birth weight standardized for sex and
gestational age) was defined according to Finnish stan-
dards [28].
Genotyping
A venous blood sample (36 mL) was drawn from all sub-
jects. Genomic DNA was extracted from whole blood
using the NucleoSpin Blood XL DNA extraction kit
(Macherey-Nagel GmbH & Co.) or Chemagic Magnetic
Separation Module I –machine (Chemagen) and subse-
quently stored at −20 °C. The genotyping was conducted
Fig. 1 The role of the regulator of G-protein signaling 2 (RGS2) protein
in vasoconstriction. Vasoconstrictive ligands, such as angiotensin II (AT
II), vasopressin (ADH) and norepinephrine (NE), bind to their specific
G-protein coupled receptors angiotensin II receptor type 1 (ATR1),
vasopressin receptor 1A (AVPR1A) and α1-adrenergic receptor (α1)
located in vascular smooth muscle cells. This leads to dissociation of
the active subunits of the receptor and activation of the downstream
effectors promoting vasoconstriction. The RGS2 protein enhances GTP
hydrolysis in the Gα subunit inhibiting the dissociation of the subunits
and therefore inhibiting vasoconstriction
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at the Institute for Molecular Medicine Finland, Technol-
ogy Centre, University of Helsinki, using the MassARRAY
iPLEX method (Sequenom, San Diego, CA, USA).
Statistical methods
Using the genetic power calculator [29] it was estimated
that with a risk allele (G) frequency of 0.27 and pre-
eclampsia prevalence of 5 %, our sample size of 1339
preeclampsia patients and 697 controls is sufficient to
detect an effect size of 1.25 for the GC genotype and 1.5
for the GG genotype of rs4606 with power >80 % when
α < 0.05 (dominant 1df test). Power calculation was
based on the risk allele frequency of rs4606 in the
European population according to the 1000 Genomes
database [30], and on the effect sizes observed in the
study by Kvehaugen et al. [13].
The Hardy-Weinberg test was performed using the
PLINK [31] software. For the clinical characterization of
the sample set, continuous variables were compared
using the Mann–Whitney U test due to skewed distribu-
tions, and categorical variables using the chi-square test
or the Fisher’s exact test. The allelic and genotypic asso-
ciation of rs4606 with preeclampsia was tested using
binary logistic regression. Dominant, recessive and addi-
tive genetic models were utilized in the genotypic associ-
ation test. For all tests, a p value <0.05 was considered
statistically significant. Statistical analyses were per-
formed with SPSS Statistics 22 software (IBM Corp.).
Results
Background characteristics of the study population
Basic maternal and perinatal background characteristics
of the study participants are presented in Table 1. The
preeclampsia group had a higher mean prepregnancy
BMI and higher rates of gestational diabetes than the
group of control subjects. Preeclamptic women also de-
livered on average earlier and had smaller placentas, and
their infants had lower relative birth weights than those
of the controls. There were significantly fewer women
who smoked before pregnancy amongst the primiparous
preeclamptic women compared to the primiparous
controls.
Association of the RGS2 rs4606 polymorphism with
preeclampsia and body mass index
Rs4606 was successfully genotyped in 1324 (98.9 %) pre-
eclamptic and in 694 (99.6 %) control women. The allele
frequencies were found to be in Hardy-Weinberg equi-
librium. The frequency of the risk allele G was 0.23. No
association between rs4606 and preeclampsia was found
under a dominant (Table 2), recessive or additive genetic
model (data not shown).
Table 1 Maternal and perinatal background characteristics of the study groups
Preeclampsia Control
Primipara Multipara Primipara Multipara Primipara Multipara
(n = 987) (n = 352) (n = 377) (n = 320) P values P values
Maternal characteristics
Age, y 30 (26/33) 33 (30/38) 29 (25/32) 31 (28/35) 0.020 <0.001
Body mass index, kg/m2 23.6 (21.2/27.3) [985] 24.8 (22.1/29.4) [351] 23.0 (21.0/25.7) 22.8 (20.7/26.2) 0.006 <0.001
Highest systolic blood pressure, mmHg 165 (153/178) 166 (156/180) 126 (119/134) 124 (117/131) <0.001 <0.001
Highest diastolic blood pressure,
mmHg
109 (104/116) 109 (103/116) 83 (78/88) 81 (77/86) <0.001 <0.001
Highest proteinuria, g/24 h 3.1 (1.4/6.2) [887] 2.9 (1.1/5.6) [305] 1.0 (0.8/1.6) [4] 0.6 [2] N/A N/A
Smoking before pregnancy 172 (18.3) [941] 48 (14.6) [328] 90 (24.8) [363] 44 (14.5) [304] 0.008 0.954
Smoking during pregnancy 58 (6.1) [948] 26 (7.8) [333] 28 (7.5) [371] 26 (8.4) [308] 0.345 0.769
Chronic hypertension 151 (15.3) 85 (24.1) … … … …
Gestational diabetes mellitus 116 (11.8) 69 (19.6) 29 (7.7) 24 (7.5) 0.030 <0.001
Pregestational diabetes mellitus 24 (2.4) 16 (4.5) 4 (1.1) 1 (0.3) 0.136 <0.001
Placental weight, g 495 (400/600) [951] 500 (390/615) [338] 590 (500/669) [363] 628 (554/720) [314] <0.001 <0.001
Placental insufficiency 94 (9.5) 50 (14.2) … … … …
Perinatal characteristics
Gestational age at birth, weeks 37.9 (35.4/39.3) [986] 37.4 (34.6/39.0) 40.6 (39.6/41.3) 40.3 (39.4/41.1) <0.001 <0.001
Birth weight, g 2775 (2185/3280) 2790 (1882/3384) 3520 (3245/3851) 3730 (3416/4022) <0.001 <0.001
Relative birth weight (SD) −1.1 (−1.9/−0.4) [986] −1.1 (−1.9/0.0) [350] −0.2 (−0.7/0.5) 0.3 (−0.3/0.9) <0.001 <0.001
Values for continuous variables are median (25th/75th percentile) and for categorical variables frequencies (%). Number of subjects with data is shown in brackets
if different from the total number
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A significant association of the CG and GG genotypes
with preeclampsia was seen in the subgroup of
overweight women under a dominant model (Table 2).
No association was detected when obese subjects were
included in the analysis. The CG and GG genotypes
were not statistically significantly associated with BMI
categories in the control group.
In moderated multiple regression analysis where we
investigated the effect of genotype (dominant model),
categorical BMI and the interaction between the geno-
type and categorical BMI on the risk of preeclampsia,
BMI as a categorical variable was found to significantly
increase the risk (p < 0.001). Interaction analysis did not
provide robust evidence on differing effects of the
rs4606 risk genotype on preeclampsia risk in different
BMI categories, although the p value for the interaction
effect was close to significance (p = 0.069).
Discussion
In this study, CG and GG genotypes of the RGS2 3′ UTR
polymorphism rs4606 were not associated with pre-
eclampsia when all study participants were included in the
analysis. However, the association with preeclampsia was
seen in the subgroup of overweight women.
The strengths of this study include a clinically well-
characterized ethnically homogenous study population
with extensive clinical and background information
available on each study participant. The participants
were recruited from all Finnish university hospitals and
therefore could be considered representative of the
Finnish population. Frequency of the risk allele G of
rs4606 was lower in the Finnish sample set (0.23) than
in the 1000 Genomes European data (0.27) [30] utilized
in the power calculation, but our data set still had
decent statistical power of 0.79 to detect effect sizes of
1.25 for the GC genotype and 1.5 for the GG genotype
when α < 0.05 (dominant 1df test).
Although we detected association of CG or GG
genotype with preeclampsia in overweight women, this
association was not seen in obese women. The CG and
GG genotypes were not associated with BMI categories
in the control group, suggesting that the risk genotype
increases preeclampsia susceptibility by a mechanism
other than increasing BMI. Moderator analyses evaluat-
ing interaction between the rs4606 genotype and cat-
egorical BMI on preeclampsia risk were inconclusive.
We speculate that obesity, a complex trait, which in
itself is a risk factor for preeclampsia might override the
influence of one genetic variant on preeclampsia suscep-
tibility. Nonetheless, this finding needs further investiga-
tion in other clinically well-characterized preeclampsia
cohorts.
Rs4606 has previously been associated with pre-
eclampsia and recurrent preeclampsia in a Norwegian
population [13]. The total sample size in the present
study was somewhat smaller than that available in the
study by Kvehaugen et al. [13], which may have contrib-
uted to our failure to replicate this finding. Another
possibility is that the effects of rs4606 polymorphism on
the risk of preeclampsia are modified by some population-
specific genetic or other factors. Detailed clinical informa-
tion was lacking in part of the Norwegian study popula-
tion, and therefore their study could not assess the
association of rs4606 genotypes with preeclampsia in
overweight women. However, this subgroup of parturients
should be examined also separately, since being over-
weight prior to pregnancy is a risk factor for preeclampsia
[12, 32] and predicts later metabolic syndrome [33]. Fur-
thermore, the changes in lipid and insulin metabolism
seen in preeclampsia suggest a state of increased insulin
resistance similar to the metabolic syndrome [1, 34] and
persist several years postpartum [35, 36]. In accordance
with these observations, prior preeclampsia elevates the
risk of cardiovascular diseases and impaired glucose me-
tabolism in later life [37–40]. Taking into account these
apparent inter-linkages between obesity, insulin resistance
and preeclampsia, it is possible that rs4606 is one of the
genetic risk factors with small effect size that contribute
Table 2 Association of the RGS2 rs4606 genotypes with all preeclampsia patients and in groups divided by BMI
BMI category na CC GG or CG OR (95 % CI) P
All Preeclampsia 1324 780 (58.9) 544 (41.1) 1.109 (0.919–1.338) 0.282
Control 694 426 (61.4) 268 (38.6)
Normal weight (BMI < 25 kg/m2) Preeclampsia 784 484 (61.7) 300 (38.3) 0.971 (0.769–1.226) 0.806
Control 480 293 (61.0) 187 (39.0)
Overweight (BMI≥ 25 kg/m2 and < 30 kg/m2) Preeclampsia 310 162 (52.3) 148 (47.7) 1.635 (1.103–2.423) 0.014
Control 159 102 (64.2) 57 (35.8)
Obese (BMI≥ 30 kg/m2) Preeclampsia 227 133 (58.6) 94 (41.4) 0.913 (0.504–1.655) 0.764
Control 55 31 (56.4) 24 (43.6)
Binary logistic regression: preeclampsia patients vs control subjects, dominant model. Number of subjects and frequencies (%) are presented. OR indicates
odds ratio, CI confidence interval and BMI body mass index. aAltogether 1324 preeclamptic and 694 non-preeclamptic women were successfully genotyped.
BMI information was missing for 3 preeclamptic cases (1 CC and 2 CG genotypes)
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to a maternal constitution susceptible to develop pre-
eclampsia in the presence of a metabolic risk factor,
overweight. Interestingly the −391 C to G substitution in
the promoter of RGS2 has been associated with metabolic
syndrome in white European men [41] and the rs4606 CG
or GG genotypes have been found to predict weight gain
in young hypertensive men [24].
Several biological mechanisms, such as activation of
renin-angiotensin system (RAS) and sympathetic ner-
vous system, are involved in the development of obesity-
related hypertension (reviewed in [42]). Adipose tissue is
an important source for the components of the RAS
system, which main effector is angiotensin II [43], a
vasoconstrictor in the RGS2-inhibited pathway. Renal
sympathetic system activation in obese individuals is
marked by increased levels of another RGS2-inhibited
vasoconstrictor, norepinephrine [44]. Taken together,
being overweight increases the release of vasoconstrict-
ive agents to which overweight women with low RGS2
levels might have impaired capacity to respond to.
The CG and GG genotypes of rs4606 have been linked
to personality traits and brain function correlated with
anxiety disorders [25] as well as to lower likelihood of
benefiting from sertraline treatment to social anxiety
disorder [45]. Overweight and obese pregnant women
might constitute a subgroup that is especially vulnerable
for comorbid anxiety [46], and anxiety and depression
have been associated with the risk of preeclampsia
[47, 48]. Unfortunately, we did not have any informa-
tion on personality traits or anxiety disorders of the
study subjects.
This study encourages further research exploring the
role of RGS2 in preeclampsia and its short- and long-
term comorbidities such as obesity, cardiovascular
disease and anxiety disorders. Heterogeneity of pre-
eclampsia poses a challenge in candidate gene association
studies. The identification of genetic variants that predis-
pose to subtypes of preeclampsia demands large DNA
collections, because the expected effect sizes of individual
sequence variants on the preeclampsia risk are small [49].
To this end, large international collaborations with
carefully characterized cohorts play a vital role.
Conclusions
In this study rs4606, an RGS2 3′UTR polymorphism
connected to low levels of RGS2, was not associated
with preeclampsia. However, this polymorphism was
associated with preeclampsia in a subgroup of over-
weight women. Our study suggests that the function of
RGS2 could be one of the factors explaining the complex
connection of preeclampsia and maternal overweight and
warrants further investigation in other clinically well-
characterized preeclampsia cohorts.
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